FDA Approval of Daraxonrasib Marks Turning Point in Pancreatic Cancer Care

For decades, a diagnosis of metastatic pancreatic cancer has been among the most devastating pronouncements in medicine. The disease is typically detected late, spreads early, and shrugs off most conventional therapies, leaving patients with few meaningful options and painfully little time. That trajectory has now changed. The United States Food and Drug Administration has approved daraxonrasib, a targeted therapy pill tested in a global clinical trial in which the Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine served as the only participating site in South Florida. According to the trial results that underpinned the approval, patients who received daraxonrasib lived nearly twice as long as patients treated with standard chemotherapy, an outcome that researchers in the field describe as a genuine inflection point for one of oncology’s most stubborn challenges.

Peter Hosein, M.D., co-leader of Sylvester’s Gastrointestinal Cancer Site Disease Group, called the approval a monumental shift in the treatment of pancreas cancer. The significance lies not only in the survival benefit itself but in what it signals about the future of the disease: pancreatic cancer, long treated as a monolith to be attacked with blunt cytotoxic chemotherapy, is increasingly being understood at the molecular level, allowing drugs designed for specific biological vulnerabilities to be matched with the patients whose tumors carry them. Targeted therapies of this kind have transformed outcomes in lung cancer, breast cancer and leukemia, and daraxonrasib’s success suggests that pancreatic oncology is finally entering that same era of precision medicine.

Even as treatment advances, earlier detection remains the field’s most urgent unmet need, and a new grant from the Pancreatic Cancer Action Network aims to address it. The organization has awarded Sylvester researchers 225,000 dollars over two years to help establish a blood test for pancreatic cancer based on circulating tumor DNA, or ctDNA. For patients with lung cancer, colon cancer and certain other solid tumors, liquid biopsies that detect fragments of tumor DNA shed into the bloodstream have become routine tools, helping oncologists identify molecular weaknesses in a tumor without invasive procedures and adjust treatment as the disease evolves. Pancreatic cancer patients have not enjoyed that advantage; invasive tissue biopsies remain the standard, and the tumors’ biology has made reliable ctDNA detection difficult.

The PanCAN-funded project seeks to change that by establishing ctDNA analysis as a dependable way to measure the molecular makeup of metastatic pancreatic cancer, one of the deadliest malignancies known. If successful, the approach could allow clinicians to track tumor evolution in near real time through simple blood draws, matching patients to targeted agents as new mutations emerge and monitoring treatment response without repeated surgical intervention. The work complements the daraxonrasib story in an important way: targeted therapies are only as useful as the molecular diagnostics that identify eligible patients, and liquid biopsies could dramatically widen the funnel of patients who benefit from drugs like the newly approved pill.

Shifting from treatment to prevention, Sylvester investigators have published sobering new data on alcohol’s role in cancer mortality. A study by the center’s researchers, first presented at the annual meeting of the American Society of Clinical Oncology and now published in The Lancet Regional Health – Americas, found that alcohol-attributable cancer deaths in the United States doubled between 1990 and 2023. Perhaps more striking than the overall trend is its demographic reach. Alcohol-linked cancer deaths are not confined to older adults or to liver cancer, the organs and populations most commonly associated with drinking-related disease in the public imagination.

Among adults aged 20 to 54, the study found that colorectal cancer was the leading alcohol-related cancer death in men, while breast cancer ranked first among women. Those findings carry substantial public health implications, because they indicate that alcohol’s carcinogenic influence operates across a wide swath of tumor types and age groups, and that the burden is falling on populations who may not perceive themselves as being at risk. Alcohol is an established carcinogen, classified as such by international cancer research bodies, and the mechanistic pathways are well described: its metabolite acetaldehyde damages DNA, alcohol consumption impairs nutrient absorption and hormone regulation, and it acts as a solvent that enhances the penetration of other carcinogens into tissues. The doubling of deaths over three decades suggests that awareness and policy responses have not kept pace with the accumulating evidence.

Against that backdrop, a second Sylvester study examined whether communication strategies could close the awareness gap. Writing in Cancer, a journal of the American Cancer Society, researchers led by Taghrid Asfar, M.D., MSPH, professor of public health, reported that online warnings about alcohol and cancer prompted stronger responses when they named specific cancers and included AI-generated images depicting health consequences. Many people remain unaware that alcohol is linked to several cancers, Asfar noted, and the study suggests that specificity matters: generic warnings about harm are less effective than messages that identify concrete diseases and pair that information with vivid visual depictions of what those diseases entail.

The work sits at the intersection of behavioral science and emerging technology, testing whether generative artificial intelligence can be harnessed to produce health communication that is both scalable and persuasive. If AI-generated imagery can meaningfully improve public understanding of alcohol’s cancer risks, health agencies could deploy tailored warning campaigns at low cost across digital platforms, reaching younger audiences precisely where the mortality data show the burden is growing. The approach also raises questions the field will need to address, including how to ensure that synthetic images used in public health messaging remain accurate and non-misleading, but the core finding, that specificity plus visual evidence improves risk comprehension, offers a practical template for campaigns aimed at other preventable risk factors as well.

Artificial intelligence is also reshaping basic discovery at Sylvester, where scientists have used computational methods and advanced laboratory experiments to illuminate a previously hidden corner of the human proteome. The protein universe contains hundreds of millions of members, yet the vast majority remain poorly characterized, a biological darkness that may conceal clues to health and disease. In research published in Nature, the Sylvester team identified a protein that helps cells form physical connections and share resources with one another, revealing an entirely new layer of cellular communication. Daniel Isom, Ph.D., the study’s senior author, said the discovery suggests there is another layer of biology that has been hiding in plain sight.

The finding demonstrates how machine learning can guide experimental biology toward targets that traditional hypothesis-driven research might never have flagged, scanning enormous sequence spaces for proteins with predicted structural features and then validating their functions in the laboratory. Because the newly characterized protein governs how cells connect and exchange resources, it could prove relevant to cancer, where communication between tumor cells and their neighbors shapes growth, survival and drug resistance. Rounding out the center’s recent output, a multicenter study published in Blood Cancer Discovery, conducted with Memorial Sloan Kettering Cancer Center and Moffitt Cancer Center, identified loss of the RHOA gene as a mechanism by which some large B-cell lymphomas evade CAR T-cell therapy, disrupting key immune responses and offering a route toward predicting and overcoming treatment resistance. Meanwhile, Sylvester researcher Melissa Lopez, Ph.D., MS, RDN, nutrition lead in lifestyle medicine at the center’s Survivorship and Supportive Care Institute, received an NCI ENICTO pilot grant to test whether routine clinical and nutritional markers from standard lab results can predict which patients will suffer the heaviest symptom burden during and after chemotherapy, a question that could make the chemotherapy journey more predictable for the many patients for whom it remains anything but uniform. Together, the September and October findings sketch a portrait of a cancer center working simultaneously at the bedside, in the clinic, and deep inside the dark proteome, with each advance feeding the others.

Subject of Research: Recent advances in pancreatic cancer therapy, alcohol-related cancer mortality, ctDNA diagnostics, AI-based protein discovery and CAR T-cell resistance research at Sylvester Comprehensive Cancer Center

Article Title: Sylvester Cancer Tip Sheet for September and October, 2026

Article References: Sylvester Cancer Tip Sheet for September and October, 2026. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: pancreatic cancer, daraxonrasib, FDA approval, targeted therapy, ctDNA, liquid biopsy, alcohol and cancer, artificial intelligence, dark proteome, CAR T-cell therapy, lymphoma, chemotherapy side effects